Phenotype/Genotype correlations in 21-hydroxylase deficiency

S.F. Siegel M.D. , P.A. Lee M.D., Ph.D. , W.A. Rudert M.D., Ph.D. , M. Swinyard M.D. , M. Trucco M.D.
{"title":"Phenotype/Genotype correlations in 21-hydroxylase deficiency","authors":"S.F. Siegel M.D. ,&nbsp;P.A. Lee M.D., Ph.D. ,&nbsp;W.A. Rudert M.D., Ph.D. ,&nbsp;M. Swinyard M.D. ,&nbsp;M. Trucco M.D.","doi":"10.1016/S0932-8610(12)80154-X","DOIUrl":null,"url":null,"abstract":"<div><p><em>Study Objective:</em> To correlate phenotype with genotype based on molecular diagnosis in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency.</p><p><em>Design:</em> Polymerase chain reaction amplification, restriction fragment length polymorphism, and allele specific oligonucleotide hybridization were utilized to ascertain eight previously recognized deleterious mutations in affected individuals and their family members.</p><p><em>Participants/Setting:</em> DNA samples were obtained from 20 individuals with 21-hydroxylase deficiency followed through the Endocrine Clinic of the Children's Hospital of Pittsburgh. Fifteen individuals had salt-losing 21-hydroxylase deficiency and two families had two affected individuals. Four individuals presented prior to 5 years of age without salt loss. One individual presented in adolescence with hirsutism and oligomenorrhea.</p><p><em>Main Outcome Measure:</em> Molecular diagnosis of 21-hydroxylase deficiency.</p><p><em>Results:</em> Five patients have homozygous deletions of the promoter region. Two patients are homozygous for the splicing mutation in the second intron. Individual patients were homozygous for the following three mutations: Arg<sup>356</sup>→Trp, Ile<sup>172</sup>→ Asn, and Val<sup>281</sup> → Leu. Ten patients were compound heterozygotes.</p><p><em>Conclusions:</em> In general, the magnitude of enzyme activity correlates with the phenotypic findings. For example, mutations that completely impair enzyme activity, such as homozygous deletions of the promoter region, are associated with salt-losing congenital adrenal hyperplasia. However, the splicing mutation at nucleotide 655 in the second intron is characterized by greater phenotypic heterogeneity than the other mutations in this series.</p></div>","PeriodicalId":80358,"journal":{"name":"Adolescent and pediatric gynecology","volume":"8 1","pages":"Pages 9-16"},"PeriodicalIF":0.0000,"publicationDate":"1995-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S0932-8610(12)80154-X","citationCount":"19","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Adolescent and pediatric gynecology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S093286101280154X","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 19

Abstract

Study Objective: To correlate phenotype with genotype based on molecular diagnosis in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency.

Design: Polymerase chain reaction amplification, restriction fragment length polymorphism, and allele specific oligonucleotide hybridization were utilized to ascertain eight previously recognized deleterious mutations in affected individuals and their family members.

Participants/Setting: DNA samples were obtained from 20 individuals with 21-hydroxylase deficiency followed through the Endocrine Clinic of the Children's Hospital of Pittsburgh. Fifteen individuals had salt-losing 21-hydroxylase deficiency and two families had two affected individuals. Four individuals presented prior to 5 years of age without salt loss. One individual presented in adolescence with hirsutism and oligomenorrhea.

Main Outcome Measure: Molecular diagnosis of 21-hydroxylase deficiency.

Results: Five patients have homozygous deletions of the promoter region. Two patients are homozygous for the splicing mutation in the second intron. Individual patients were homozygous for the following three mutations: Arg356→Trp, Ile172→ Asn, and Val281 → Leu. Ten patients were compound heterozygotes.

Conclusions: In general, the magnitude of enzyme activity correlates with the phenotypic findings. For example, mutations that completely impair enzyme activity, such as homozygous deletions of the promoter region, are associated with salt-losing congenital adrenal hyperplasia. However, the splicing mutation at nucleotide 655 in the second intron is characterized by greater phenotypic heterogeneity than the other mutations in this series.

21-羟化酶缺乏症的表型/基因型相关性
研究目的:探讨21-羟化酶缺乏症先天性肾上腺增生患者的分子诊断中表型与基因型的相关性。设计:利用聚合酶链反应扩增、限制性片段长度多态性和等位基因特异性寡核苷酸杂交来确定患者及其家庭成员中8种先前已知的有害突变。参与者/环境:从20名21-羟化酶缺乏症患者中获得DNA样本,并通过匹兹堡儿童医院内分泌诊所进行随访。失盐21-羟化酶缺乏症15例,2个家庭2例。4名患者在5岁前未出现盐流失。一个人在青春期表现为多毛和少经。主要观察指标:21-羟化酶缺乏症的分子诊断。结果:5例患者有纯合缺失的启动子区域。2例患者的第二个内含子剪接突变为纯合子。其中Arg356→Trp、Ile172→Asn、Val281→Leu 3个突变为纯合子,10例为复合杂合子。结论:一般来说,酶活性的大小与表型结果相关。例如,完全损害酶活性的突变,如启动子区域的纯合缺失,与失盐性先天性肾上腺增生有关。然而,第二个内含子核苷酸655处的剪接突变比该系列中的其他突变具有更大的表型异质性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信